Ranbaxy Laboratories is planning to launch its first branded subscription drug in the anti-infectives segment by 2004, in the US. The drug may soon get an Investigational New Drug Application (INDA) filing and is subject to other approvals.
D S Brar, chief executive office and managing director, Ranbaxy Laboratories said, on the sidelines of a pharma seminar here,
